Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening) (NCT05139797)
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases
🩺 Plain-English Summary (8th-Grade Level)
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Centre (Los Angeles) — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- EchoNet-LVH screening for cardiac amyloidosis (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Cedars-Sinai Medical Centre (Los Angeles) — Los Angeles, California
📞 Contact the Study Coordinator
Phone: (310) 248-8300
Email: lily.stern@cshs.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiac Amyloidosis
- Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis — Boston, Massachusetts
- CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study — Charlotte, North Carolina
- [64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy — Boston, Massachusetts
- Elevated Rate Pacing of Cardiac Amyloidosis — Minneapolis, Minnesota
Explore by condition: All Cardiac Amyloidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.